Inhibikase Therapeutics (IKT) Net Margin (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Net Margin of -417794000.00% for Q4 2023, down 417787268.33 percentage points from -6731.67% a year earlier and down 417788224.89 percentage points from the prior quarter.
Inhibikase Therapeutics (IKT) Net Margin (2020 - 2026) Analysis & Trends
For FY2023, Inhibikase Therapeutics posted Net Margin of -7304.73%, up 7321.13 percentage points from FY2022.
- Net Margin has a three-year change of -6896.99 percentage points (FY2020 to FY2023).
- By year, Net Margin came in at -14625.85% in FY2022 (-14148.98 pp), -476.88% in FY2021 (-69.14 pp) and -407.73% in FY2020.
- The Q4 2023 figure ranks as the lowest quarterly Net Margin in data going back to Q1 2020.
- Year over year, Net Margin gained in four of the last eight quarters, with an average year-over-year change of -52193824.25 percentage points.
- The high point for year-over-year Net Margin in five years was Q4 2022 (a gain of 252610.87 percentage points); the low point was Q4 2023 (a drop of 417787268.33 percentage points).
- Per Business Quant data, the three quarters before Q4 2023 came in at -5775.11% (Q3 2023), -4963.46% (Q2 2023) and -6940.03% (Q1 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 26.44% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 0.83% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 24.24% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 28.01% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 20.69% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 37.28% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 29.27% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 19.55% |
| 10 | Inhibikase Therapeutics | 281.11 Mn | -420.36 Mn | - | -1,161.78% |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -1,161.78% |
| Jun 30, 2026 | -1,342.08% |
| Mar 31, 2026 | -1,121.15% |
| Dec 31, 2025 | -1,224.40% |
| Sep 30, 2025 | -1,421.97% |
| Jun 30, 2025 | -1,081.59% |
| Mar 31, 2025 | -1,488.00% |
| Dec 31, 2023 | -417,794,000.00% |
| Sep 30, 2023 | -5,775.11% |
| Jun 30, 2023 | -4,963.46% |
| Mar 31, 2023 | -6,940.03% |
| Dec 31, 2022 | -6,731.67% |
| Sep 30, 2022 | -61,645.36% |
| Jun 30, 2022 | -70,817.14% |
| Mar 31, 2022 | -10,081.47% |
| Dec 31, 2021 | -259,342.54% |
| Sep 30, 2021 | -1,361.26% |
| Jun 30, 2021 | -193.40% |
| Mar 31, 2021 | -187.40% |
| Dec 31, 2020 | -708.85% |
Inhibikase Therapeutics Net Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-margin&ticker=IKT&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-margin", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=net-margin&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();